Aurinia Pharmaceuticals Inc. AUPH
16.30 USD -0.32 (-1.93%)
At closeNov 11, 2026, 4:05 AM EST
15.69 -0.61 -3.74%
Pre-market · Nov 11, 4:05 AM ET
16.24 Day range 16.68
13.52 52-week range 19.25
- YTD
- +2.19%
- 1 year
- +9.47%
News
benzinga.com Why Is Teva Stock Trading Lower on Monday? Teva halts its Phase 2 TOPAS-MSA study after an interim futility analysis showed low odds of meeting the primary efficacy endpoint.
benzinga.com RBC Capital Maintains Sector Perform on Aurinia Pharmaceuticals, Raises Price Target to $18 RBC Capital analyst Douglas Miehm maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Sector Perform and raises the price target from $16 to $18.
benzinga.com Aurinia Pharmaceuticals Raises FY2026 Sales Guidance from $315.000M-$325.000M to $325.000M-$330.000M vs $330.261M Est Aurinia Pharmaceuticals (NASDAQ:AUPH) raises FY2026 sales outlook from $315.000 million-$325.000 million to $325.000 million-$330.000 million vs $330.261 million estimate.- benzinga.com Aurinia Pharmaceuticals Q3 EPS $0.23 Beats $0.22 Estimate, Sales $83.699M Beat $83.691M Estimate Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.22 by 4.55 percent. This is unchanged from the same period last…
- benzinga.com TD Cowen Maintains Buy on Aurinia Pharmaceuticals, Raises Price Target to $18 TD Cowen analyst Stacy Ku maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy and raises the price target from $17 to $18.